As AI spreads across biopharma, what will matter most is not who has the flashiest tools, but who can use them to make better medicines. In this episode of The BioCentury Show, Recursion CEO Najat Khan discusses where AI is showing measurable value now, how public techbio companies are being pushed toward proof points, and what comes next — from out-of-domain prediction to stronger data foundations and precompetitive collaboration.
View full story: https://www.biocentury.com/article/658829
#ArtificialIntelligence #DrugDevelopment #AgenticAI #ClinicalProof #BiopharmaInnovation
00:00 - Introduction
01:41 - AI Hype to Proof
04:52 - Where AI Adds Value
13:30 - AI for Clinical Trials
17:01 - Agentic AI in R&D
25:34 - Out-of-Domain Prediction
28:24 - Future of Techbio
31:13 - Precompetitive Consortia
35:24 - CEO Leadership and Catalysts
